Yahoo Web Search

Search results

    • Beyond BCMA-Directed CAR T-Cell Therapy

      Beyond BCMA-Directed CAR T-Cell Therapy

      MedPage Today· 3 days ago

      Although survival rates for patients with multiple myeloma are improving, with a 5-year rate of about 60%, many patients relapse after treatment....

    • Argenx soars on CIDP shot approval

      Investing.com via Yahoo Finance· 6 hours ago

      “The label for Vyvgart CIDP represents the best case scenario in management's view,” said analysts at UBS, in a note dated June 24. “The label is for broad CIDP patients without ...